- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
PDS Biotechnology Corporation today announced that the company has been selected as a collaborator of the US National Cancer Institute's Nanotechnology Characterization Lab (NCL) to complete preclinical development of Versamune(TM)-HPV prior to filing of the Investigational New Drug Application. The NCL will perform selected physical, chemical and biological studies on behalf of the company at its facilities at the National Cancer Institute (NCI) in Frederick, Maryland. Dr. Frank Bedu-Addo, President of the Corporation stated that, "PDS Biotechnology Corporation's partnership with the NCL provides significant value to the company. The invaluable expertise of the NCL's scientists will provide the company with additional expert resources and technologies, and will facilitate rapid development of the product."
Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers caused by infection with the human papilloma virus (HPV) include cervical, head and neck and anal cancers. No cures exist for these cancers. Based on promising in vivo and in vitro efficacy data, PDS Biotechnology Corporation was awarded in August 2008, a phase I SBIR grant by the US National Institutes of Health/National Cancer Institute to develop Versamune(TM)-Melanoma to treat melanoma, which is the most aggressive form of skin cancer.
PDS Biotechnology Corporation's Versamune(TM) nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen- presenting cells of the immune system and simultaneously acts a strong immune system activator (adjuvant) without the inflammatory side effects induced by current adjuvants. The result is simple, safe and cost effective nanotechnology-based drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular protein formulated with Versamune(TM).
About PDS Biotechnology Corporation
PDS Biotechnology Corporation (www.pdsbiotech.com) is a Cincinnati, Ohio-based biotechnology company applying the company's proprietary Versamune(TM) nanotechnology drug platform technology to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.
The NCL is a formal collaboration between the US National Cancer Institute, the US Food and Drug Administration (FDA) and the National Institute of Standards and Technologies (NIST) to rapidly advance promising cancer nanotechnology drugs through regulatory submissions with the FDA.
For more information, please click here
PDS Biotechnology Corporation
3130 Highland Avenue
Cincinnati, Ohio 45219
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Graphene under pressure August 26th, 2016
Stretchy supercapacitors power wearable electronics August 25th, 2016
Scientists uncover origin of high-temperature superconductivity in copper-oxide compound: Analysis of thousands of samples reveals that the compound becomes superconducting at an unusually high temperature because local electron pairs form a 'superfluid' that flows without resist August 19th, 2016
Let's roll: Material for polymer solar cells may lend itself to large-area processing: 'Sweet spot' for mass-producing polymer solar cells may be far larger than dictated by the conventional wisdom August 12th, 2016
NREL technique leads to improved perovskite solar cells August 11th, 2016
New approach to determining how atoms are arranged in materials August 25th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016